Abstract 294P
Background
We aimed to assess the safety and preliminary efficacy of cisplatin every 3 weeks in concurrent chemoradiation in cervical cancer in the era of modern radiotherapy techniques such as IMRT/VMAT.
Methods
This is a single-arm phase 2 clinical trial which included patients with stage IB3-IVA cervical cancer at Vietnam National Cancer Hospital. Neuroendocrine carcinoma was excluded. Patients were treated with definitive chemoradiotherapy with cisplatin 75mg/m2, day 1, 22 and 43 concurrently with external beam radiotherapy and brachytherapy. Treatment completion rate, response rate and toxicities were assessed.
Results
A total of 38 patients were included, with a mean age of 53.3 years (range 33-71). The mean tumor size was 4.31 ± 0.87 cm. Stage IB3, II and III accounted for 2.6%, 44.7% and 52.6% respectively. Thirty-seven patients (97.3%) completed planned treatment protocol, with the mean total time of radiation therapy of 49.8 ± 5.9 days. At 1 month after treatment, the complete clinical response rate was 84.2% (32/38 patients), partial response was recorded in 4 patients with stage IIIC1 and 2 patients with stage IIB. Among these 6 patients, 4 cases had complete response at 3 months after treatment. Grade 3 toxicity included neutropenia (15.8%) and vomiting (13.2%), no febrile neutropenia or life-threatening toxicities were recorded.
Conclusions
Concurrent chemoradiation with cisplatin every 3 weeks is a safe and feasible therapy for locally advanced cervical cancer and might be suitable for places with shortage of facilities and human resources in chemotherapy infusion unit. A larger randomized controlled trial should be done to confirm the efficacy of the 3-weekly schedule.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract